Octreotide, a somatostatin analog, reduces insulin secretion and increases renal na+ excretion in lean essential hypertensive patients

American Journal of Hypertension

Volumn 6, Issue 4, 1993, Pages 276-281

  Ferri, Claudio ^b   Mattia, Giancarlo De ^a   Oriana Laurenti, Cesare Bellini ^b   Bravi, Cristina ^a   Bonavita, Roberta Baldoncini Maria S ^b   Santucci, Anna ^b   Balsano, Francesco ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Hyperinsulinemia; Hypertension; Insulin; Octreotide; Sodium excretion; Somatostatin

Indexed keywords

OCTREOTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; MALE; SODIUM EXCRETION;

ADULT; BODY WEIGHT; DOUBLE-BLIND METHOD; HUMAN; HYPERTENSION; INSULIN; KIDNEY; MALE; MIDDLE AGE; OCTREOTIDE; REFERENCE VALUES; SODIUM;

EID: 0027289297     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/6.4.276     Document Type: Article

References (19)

1. Reaven G. M: Role of abnormalities of carbohydrate and lipoprotein metabolism in the pathogenesis and clinical course of hypertension. J Cardiovasc Pharmacol 1990;15(suppl 5):S4-S7.
2. Santucci A, Ferri C: Insulin resistance and essential hypertension: pathophysiologic and therapeutic implications. J Hypertens 1992;10(suppl 2):S9-S15.
3. Ferrannini E, Buzzigoli G, Bonadonna R, et al: Insulin resistance in essential hypertension. N Eng J Med 1987;317:350-357.
4. Modan M, Halkin H, Almog S, et al: Hyperinsulinemia. A link between hypertension, obesity, and glucose tolerance. J Clin Invest 1985;75:809-817.
5. Liang C. S, Doherty J. U, Faillace R: Insulin infusion in conscious dogs: effects on systemic and coronary haemodynamics, regional blood flows, and plasma catecholamines. J Clin Invest 1982;69:1321-1336.
6. Landsberg L: Hyperinsulinemia: possible role in obesity - induced hypertension. Hypertension 1992;19(suppl I):I- 61-1-66.
7. DeFronzo R. A: The effect of insulin on renal sodium metabolism. Diabetologia 1981;21:165-171.
8. Levinson P. D, Iosiphidis A. H, Gann D. S: Hormone and cathecolamine responses accompanying the antinatriur- esis of glucose ingestion. Am J Hypertens 1989;2:178- 181.
9. Reaven G. M, Ho H, Hoffmann B. B: Somatostatin inhibition of fructose-induced hypertension. Hypertension 1989;14:117-120.
10. Carretta R, Fabris B, Fischetti F, et al: Reduction of blood pressure in obese hyperinsulinaemic hypertensive patients during somatostatin infusion. J Hypertens 1989;7(suppl 6):S196-S197.
11. Santucci A, Ferri C, Cammarella I, et al: Plasma atrial natriuretic peptide in young normotensive subjects with a family history of hypertension and in young hypertensive patients. Am J Hypertens 1990;3:782-785.
12. Rocchini A. P, Katch V, Kveselis D, et al: Insulin and renal sodium retention in obese adolescents. Hypertension 1989;14:367-374.
13. Bauer W, Briner U, Doefner W, Haller R, et al: SMS 201995. A very selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:133-140.
14. Kutz K, Nuesch E, Rosenthaler J: Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986;21(suppl 119):65-72.
15. Eriksson L. S, Wahren J: Intravenous and subcutaneous administration of a long-acting somatostatin analogue: effects on glucose-metabolism and splanchnic haemodynamics in healthy subjects. Eur J Clin Invest 1989;19:213-219.
16. Gordon P. H, Comi R. J, Matom P. M: Somatostatin and somatostatin analogue (SMS-201-995) in treatment of hormone secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989;110:35-50.
17. Sieber C, Gnadinger M, Del Pozo E, et al: Effect of a new somatostatin analogue SMS 201-995 (sandostatin) on the renin-aldosterone axis. Clin Endocrinol 1988,28:2532.
18. Maurer R, Reubi J. C: Somatostatin receptors in the adrenal. Mol Cell Endocrinol 1986;45:81-90.
19. Goodfriend T. L, Ball D. L, Weinberger M. H, et al: Salt loads raise plasma fatty acids and lower insulin. Hypertension 1991;17:958-964.